Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Avera and Avera Health Plans transitioned to a new combined patient and member portal as of May 30, 2026. If you haven’t already, create an account and reset your proxy access. Learn how to sign up at Avera.org/MyChart.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (6)

Showing 1-6 of 6

Sorted By:

A-Z
Z-A

Previous Next

BI 1479-0012 (Beamion BCGC-1): A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)
Phase II Trial of Oral Zongertinib Alone/Combo W/Other Agents for Pts w/Adv HER2+ mBC, met. Gastric, GJ, mGEAC, or mCRC
C6461003: AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
PH 3 STUDY TO EVAL PF-08634404 IN COMBINATION W/ CHEMOTHERAPY VS BEVACIZUMAB IN COMBINATION W/ CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS W/ METASTATIC COLORECTAL CANCER
GS-US-741-7756: A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Ph 2 Study Evaluate the Efficacy & Safety of Denikitug Monotherapy a& Denikitug-based Combinations in Pts w/ Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A RPhase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With/Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NRG-GI008: This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Phase 2/3 trial will evaluate which chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer
SGNTUC-029 (MOUNTAINEER-03): An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
If tucatinib w/ other cancer drugs works better than SOC to treat HER2 positive colorectal cancer. Also looks at side effects that happen with this combination of drugs.

Previous Next